Showing results (281-290 of 297) with videos related to
Sort By:
Pageof 30
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2021
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 StudyYunpeng Yang, Jiya Sun, Zhehai Wang, et al.Cancer Pathogenesis and Therapy|July 23, 2025
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trialYuankai Shi, Minghong Bi, Qingshan Li, et al.Therapeutic Advances in Medical Oncology|March 29, 2020
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)Xiang Wang, Ruixing Zhang, Nan Du, et al.American Journal of Cancer Research|April 9, 2020
Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)Xiang Wang, Junyan Yu, Mudan Yang, et al.Cancer Cell|October 15, 2024
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trialXiaobin Shang, Yongjie Xie, Jinpu Yu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2020
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)Yunpeng Yang, Zhehai Wang, Jian Fang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.The Lancet. Respiratory Medicine|December 21, 2020
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Cancer Communications (London, England)|November 4, 2022
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen, et al.The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.Pageof 30